### Index

<table>
<thead>
<tr>
<th>Term/Phrase</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>acute stroke</td>
<td>5, 104–11</td>
</tr>
<tr>
<td>cerebral hemodynamic changes</td>
<td>106–8, 111</td>
</tr>
<tr>
<td>CPAP therapy</td>
<td>108–9, 110, 123</td>
</tr>
<tr>
<td>deterioration</td>
<td>104–5</td>
</tr>
<tr>
<td>pathogenic mechanisms</td>
<td>106–8</td>
</tr>
<tr>
<td>predictors</td>
<td>106</td>
</tr>
<tr>
<td>sleep apnea predicting</td>
<td>105–8, 133–5</td>
</tr>
<tr>
<td>intracranial arterial blood steal</td>
<td>107–8, 110–11</td>
</tr>
<tr>
<td>management of sleep apnea</td>
<td>109–10, 135–6</td>
</tr>
<tr>
<td>noninvasive ventilation</td>
<td>108–9</td>
</tr>
<tr>
<td>oxidative stress</td>
<td>16</td>
</tr>
<tr>
<td>sleep apnea prevalence</td>
<td>128, 129, 130</td>
</tr>
<tr>
<td>vascular inflammation/oxidized LDL</td>
<td>17</td>
</tr>
<tr>
<td>adenotonsillectomy</td>
<td></td>
</tr>
<tr>
<td>blood pressure after</td>
<td>56, 58</td>
</tr>
<tr>
<td>pulmonary artery pressure after</td>
<td>59</td>
</tr>
<tr>
<td>adhesion molecules</td>
<td>22–3</td>
</tr>
<tr>
<td>affective disorders, restless legs syndrome and</td>
<td>147–8</td>
</tr>
<tr>
<td>age differences</td>
<td></td>
</tr>
<tr>
<td>hypertension and sleep apnea association</td>
<td>52</td>
</tr>
<tr>
<td>patient foramen ovale incidence</td>
<td>85–6</td>
</tr>
<tr>
<td>stroke and patent foramen ovale association</td>
<td>86–7</td>
</tr>
<tr>
<td>airway obstruction</td>
<td></td>
</tr>
<tr>
<td>pathophysiological effects</td>
<td>99</td>
</tr>
<tr>
<td>sleep apnea, mechanisms</td>
<td>98</td>
</tr>
<tr>
<td>amnesia, transient global</td>
<td>88</td>
</tr>
<tr>
<td>angiotensin II (Ang II)</td>
<td>19</td>
</tr>
<tr>
<td>antioxidant activity, reduced</td>
<td>14</td>
</tr>
<tr>
<td>antithrombotic therapy</td>
<td>93</td>
</tr>
<tr>
<td>anxiety, restless legs syndrome and</td>
<td>147–8</td>
</tr>
<tr>
<td>apnea/hypopnea index (AHI)</td>
<td>12</td>
</tr>
<tr>
<td>cardiovascular disease risk and</td>
<td>65</td>
</tr>
<tr>
<td>hypertension risk and</td>
<td>52</td>
</tr>
<tr>
<td>stroke patients</td>
<td>127–31, 133–4</td>
</tr>
<tr>
<td>stroke risk and</td>
<td>12, 65, 67, 131–3</td>
</tr>
<tr>
<td>arousals</td>
<td>71–6</td>
</tr>
<tr>
<td>personal story of stroke</td>
<td>152, 153</td>
</tr>
<tr>
<td>RLS/PLMS and</td>
<td>141, 145–6</td>
</tr>
<tr>
<td>stroke pathogenesis</td>
<td>71, 72–5</td>
</tr>
<tr>
<td>upper airway obstruction</td>
<td>3, 71–6, 99</td>
</tr>
<tr>
<td>arrhythmias</td>
<td></td>
</tr>
<tr>
<td>C-reactive protein, high-sensitivity (hsCRP)</td>
<td>17–19</td>
</tr>
<tr>
<td>Canadian Neurological Scale</td>
<td>104</td>
</tr>
<tr>
<td>cardiac arrhythmias</td>
<td>70, 87–8</td>
</tr>
<tr>
<td>see also atrial fibrillation</td>
<td></td>
</tr>
<tr>
<td>cardiac consequences, sleep apnea</td>
<td>99–100</td>
</tr>
<tr>
<td>cardiovascular disease (CVD) RLS/PLMS and</td>
<td>139–48</td>
</tr>
<tr>
<td>epidemiology</td>
<td>140–4</td>
</tr>
<tr>
<td>possible mechanisms</td>
<td>144–8</td>
</tr>
<tr>
<td>sleep apnea and autonomic mechanisms</td>
<td>33–44</td>
</tr>
<tr>
<td>proatherogenic mechanisms</td>
<td>26</td>
</tr>
<tr>
<td>protective mechanisms</td>
<td>25</td>
</tr>
<tr>
<td>risk factor status</td>
<td>11, 65, 131</td>
</tr>
<tr>
<td>see also cerebrovascular disease; hypertension; stroke</td>
<td></td>
</tr>
<tr>
<td>carotid body, oxygen sensing</td>
<td>41</td>
</tr>
<tr>
<td>catecholamines</td>
<td>70, 100, 116</td>
</tr>
<tr>
<td>CD40 ligand, soluble (sCD40L)</td>
<td>70</td>
</tr>
</tbody>
</table>
central sleep apnea (CSA)
poststroke patients 130
stroke risk and 133
cerebral hemodynamics
acute stroke deterioration 5, 106–8
sleep apnea 4–5
cerebral ischemia
on awakening 92
see also stroke; transient ischemic attack
cerebral protective mechanisms 25
cerebral small-vessel disease 4, 97–102
cerebral white matter lesions
patent foramen ovale 89–90
sleep apnea 98
cerebrovascular disease
autonomic mechanisms 33–44
CPAP therapy and 122–4
proatherogenic mechanisms 11, 26
protective mechanisms 25
see also stroke; transient ischemic attack
chemoreceptor reflexes 40–1, 99, 100
Cheyne-Stokes breathing 130
children see pediatric patients
chronic kidney disease 139–40
chronic obstructive pulmonary disease (COPD) 89
circadian rhythms
hormone levels 36
stroke timing and 70
cognitive dysfunction 4, 97, 101–2
continuous positive airways pressure (CPAP) 5–6, 12, 115–24
acute stroke 108–9, 110, 123, 135–6
arousal threshold after 71
atipral fllbrlation 5, 122
blood pressure changes after 5, 55–6, 116–19
glucose metabolism after 119–21
oxidative stress markers and 15
patent foramen ovale 92–3
poststroke sleep apnea 6, 67–8, 135
pregnancy 58
pulmonary artery pressure effects 59
stroke occurrence after 122–4
stroke risk factors and 5, 115–22
coronary artery bypass surgery 80–1
cortisol 36, 100, 146–7
CPAP see continuous positive airways pressure
cytokines, proinflammatory 21–2
daytime sleepiness see excessive daytime somnolence
decompression illness 88
deep vein thrombosis (DVT) 87, 92, 154
dementia 98, 102
see also cognitive dysfunction
depression, restless legs syndrome and 147–8
diabetes mellitus
restless legs syndrome and 144, 147
type 2, CPAP therapy 119–21
diuretics 57
dyslipidemia, CPAP therapy 121
E-selectin 22
eczacy (methyleneoxy-methamphetamine; MDMA) 74–5
edema, peripheral, treatment 56–7
endothelial cells, adhesion molecules 22–3
endothelial dysfunction 23–4, 44
endothelial progenitor cells (EPCs) 24
endothelin 100
epinephrine (adrenaline) 100
Epworth sleepiness scale (ESS) 53
erthropoietin (EPO) 20
European Cooperative Acute Stroke Study (ECASS) 104
excessive daytime somnolence (EDS)
acute stroke deterioration and 108
autonomic impairment 42–3
factor V Leiden gene mutation 88
fat embolism syndrome 89
fetal familial insomnia 97
fibrinogen 19
fibrinolysis 19
forem ovale 85–6
patent see patent foramen ovale
four-variable screening tool 54
gender differences, vascular inflammation 18
glucose metabolism, effects of CPAP 119–21
heart failure 57, 145
heart rate (HR)
normal sleep 48
RLS/PLMS and 145–6
sleep apnea 36–7
variability 38–9, 146
heart transplant recipients 145
hemodynamic changes
sleep apnea 36–7, 48–9, 100
see also blood pressure
high-altitude pulmonary edema (HAPE) 89
high density lipoprotein (HDL) dysfunction 17
homocysteine, plasma levels 101
hormones, during sleep 36
hyperaldosteronism, treatment 56–7
hypocapnia
arousal response 72–5, 99
sympathetic activation 41
hypercholesterolemia, CPAP therapy 121
hypercoagulability 19, 102
hypertension 2, 100
autonomic instability and 41–2, 49, 59, 116
baroreflex function and 41
daytime 49–50
daytime sleepiness and 43
effects of CPAP 5, 55–6, 116–19
effects of OSA treatment
55–7
morning 49
nocturnal 49
obesity and sleep apnea 51
populations at risk 51–3
predictors of sleep apnea 51–5
pregnancy 57–8
resistant 50, 52, 57, 119
RLS/PLMS and 144–5
epidemiology 140–4
possible mechanisms 144–8
screening for OSA 53–5
see also blood pressure
hypothalamic–pituitary–adrenal (HPA) axis, restless legs syndrome 146–7
hypoxemia
obstructive sleep apnea 99
patent foramen ovale 89
hypoxia
arousal response 76
intermittent see intermittent hypoxia
hypoxia-inducible factor-1a (HIF-1a) 21
inflammation, vascular 1–2, 16–23, 44, 101
inherited prothrombotic disorders 88
inspiration, respiratory 98
insulin resistance, effects of CPAP 119–21
integrins, β2 22
intercellular adhesion molecule-1 (ICAM-1) 22
interleukin-6 (IL-6) 21
interleukin-10 (IL-10) 21–2
interleukin-12 (IL-12) 22
intermittent hypoxia (IH)
carotid body effects 41
endothelial progenitor cells 24
oxidative stress 14–16
proatherogenic mechanisms 11, 26
sympathetic activation 40–1
vascular inflammation 16, 20
International Restless Legs Syndrome Study Group (IRLSSG) 141, 144
intracranial arterial blood flow steal 107–8, 110–11
intracranial atherosclerotic disease (IAD) 105
intrathoracic pressure, fluctuations 82, 99–100
ischemia/reperfusion injury, oxidative stress 13–14
ischemic preconditioning (IPC) 11–25
kidney disease, chronic 139–40
L-selectin disease 22
lacrimal stroke 98
lectin-like oxidized LDL receptor-1 (LOX-1) 17
left atrial enlargement 82, 100
left ventricular wall thickening/diastolic dysfunction 100
leptin 51, 101
leukocytes, adhesion molecules 22–3
lipid peroxidation 15
lipids, blood, effects of CPAP therapy 121
low density lipoprotein (LDL) 14–16
oxidized (oxLDL) 16–17
melatonin 36
memory 97
metabolic syndrome
restless legs syndrome and 144
sleep apnea association 52, 54, 101
stroke pathogenesis 68
methylenedioxy-methamphetamine (MDMA; ecstasy) 74–5
migraine with aura 88
Mueller maneuver 2, 48, 92, 99
multi-infarct dementia 98
myocardial infarction 89
NADPH oxidase 15
National Institutes of Health Stroke Scale (NIHSS) score 104–5
nitric oxide (NO) 13, 23, 24
nitrosative stress 13, 15
noninvasive ventilation
acute stroke 108–9, 110
see also continuous positive airways pressure
non-rapid eye movement (NREM) sleep arousal response 71
autonomic function 34, 35–6
norepinephrine (noradrenaline) 38, 100, 116
nuclear factor-kappaB (NF-κB) 20
obesity
C-reactive protein 18
insulin resistance and CPAP therapy 120
restless legs syndrome and 147
sleep apnea and 97, 101
sleep apnea and hypertension 51, 52, 54
obesity hypoventilation syndrome (OHS) 58–9
obstructive sleep apnea (OSA) 12–13
acute stroke deterioration and 105–8, 133–5
acute stroke patients 129, 130
arousal response see arousals
atrial fibrillation and 8, 30–83
autonomic changes 2, 33–44, 48–9, 100
cardiovascular risk 65, 131
cerebral small-vessel disease 4, 97–102
characteristics 12, 33–4
definition 12, 98
hemodynamic consequences 36–7, 48–9, 100
hypertension see hypertension
paradoxical embolism and 91–2
patent foramen ovale and 91–2
pathogenic mechanisms 99
proatherogenic mechanisms 11, 26
protective mechanisms 25
stroke patients see post-stroke sleep apnea as stroke risk factor 12–13, 64–7, 90–1, 128, 131–3
treatment see treatment of obstructive sleep apnea
oral appliance (OA) therapy, blood pressure effects 56
OSA see obstructive sleep apnea oxidative stress 13–16
oxidative stress (cont.)
- cardiovascular morbidity and stroke 16
- intermittent hypoxia models 14–16
- obstructive sleep apnea 1–2, 14–16
- oxidized low density lipoprotein (oxLDL) 16–17
- oxygen desaturation index (ODI) 12
- acute stroke patients 133
- oxygen saturation, minimal arterial (MinO2) 12

P-selectin 22
- soluble (sP-selectin) 70
- paradoxical embolism 89
- peroxides 14
- peripheral embolism 89

parasympathetic activity, paraoxinase-1 (PON1) 14

paradoxical embolism 85
- pathophysiology 106–8, 111
- predicting neurologic deterioration 105–8, 133–5
- prevalence 127–31
- treatment 6, 67–8, 135

see also acute stroke
- pramipexole 146
- pregnancy 57–8
- proinflammatory vascular risk factors 1–2, 16–23
- prothrombin gene G20210A mutation 88
- pulmonary edema, high-altitude (HAPE) 89
- pulmonary embolism 89, 92, 154

P-selectin 22
- selective serotonin reuptake inhibitors (SSRIs) 74–5
- serotonin system 73–5
- sleep
- autonomic function during
- 34–6, 48
- during stroke rehabilitation 154

sleep apnea 1
- autonomic alterations 2
- prevalence 1, 11
- stroke risk 3–4, 12–13

see also central sleep apnea;
- obstructive sleep apnea
- sleep deprivation/loss
- arousal threshold and 71
- cognitive effects 97
- RLS and PLMS 147
- Sleep Heart Health Study
- cardiovascular disease and
- sleep apnea 90, 131
- hypertension and sleep apnea
- severity 43, 50, 52
- restless legs syndrome 144
- sleep apnea and stroke risk 67, 132–3

sleep studies
- acute stroke 109, 110
- personal story of stroke 152, 153
- smoking, restless legs syndrome and 144, 148
- steal, intracranial arterial blood flow 107–8, 110–11
- STOP/STOP-BANG questionnaire 54
- stroke
- acute phase see acute stroke
- arousal phenomena and 71–6
- on awakening 92
- CPAP for prevention 122–4
- cryptogenic 86, 87
- endothelial dysfunction 23–4
- endothelial progenitor cells 24
lacunar 98
oxidative stress 16
patent foramen ovale and 86–92
pathogenic mechanisms 68–70
personal experience 7, 151–4
prevention 92–3
rehabilitation 6, 127–36
early sleep apnea therapy 135–6
effect of sleep apnea 133–5
a personal story 154
risk factors 64–76
effects of CPAP 5, 115–22
mechanisms of sleep apnea association 68–70
obstructive sleep apnea 3–4, 12–13, 64–7, 90–1, 128, 131–3
see also atrial fibrillation; hypertension; patent foramen ovale
RLS/PLMS and risk 6, 139
sleep apnea after see post-stroke sleep apnea
vascular inflammation 17, 19, 20, 21–2, 23
surgical treatment of obstructive sleep apnea 98
blood pressure changes after 56
pulmonary artery pressures after 59
see also adenotonsillectomy
sympathetic overactivity
atrial fibrillation pathogenesis 81–2
effects of CPAP 117
hypertensive effects 41, 116
obesity 51
RLS/PLMS 144–6
sleep apnea 2, 37, 39–42, 48, 100
stroke pathogenesis 68–70
sympathetic skin responses (SSRs) 35
syndrome Z 52
thermoregulation, during sleep 35–6
thiobarbituric acid-reactive substances (TBARS) 14
thrombosis 102
see also deep vein thrombosis
thrombotic disorders, inherited 88
thyroid stimulating hormone 36
TIA see transient ischemic attack
tongue, upper airway obstruction 98
traceostomy 68
transcranial Doppler (TCD) acute stroke 108, 110–11
intracranial arterial blood flow steal 107
transcription factors, redox-regulated 20
transesophageal echocardiography 85
transient global amnesia 88
transient ischemic attack (TIA) 64–7
CPAP therapy and 122–3, 135, 136
pulmonary artery pressure stroke patients 67–8, 135–6
stroke prevention 92–3
see also continuous positive airways pressure
tumour necrosis factor-a (TNF-a) 21
Valsalva maneuver 39, 87, 91, 92
vascular cell adhesion molecule-1 (VCAM-1) 22
vascular endothelial growth factor (VEGF) 20
vascular inflammation 1–2, 16–23, 44, 101
weight loss 68
Wisconsin Sleep Cohort Study 49, 50, 132
work of breathing, increased 76
xanthine oxidase 15